

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 8-K

MEDICIS PHARMACEUTICAL CORP

Form 8-K

July 15, 2004

=====

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): July 15, 2004

Medicis Pharmaceutical Corporation  
(Exact Name of Registrant as Specified in Charter)

Delaware	0-18443	52-1574808
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

8125 North Hayden Road  
Scottsdale, Arizona  
(Address of Principal  
Executive Offices)

85258-2463  
(Zip Code)

Registrant's telephone number, including area code: (602) 808-8800

N/A

-----  
(Former Name or Former Address, if Changed Since Last Report)

=====

Item 5. Other Events

On July 15, 2004, Medicis Pharmaceutical Corporation (the "Company") issued a press release announcing that it had entered into an exclusive license agreement with Q-Med AB ("Q-Med") to market, distribute, sell and commercialize in the United States and Canada Q-Med's product currently known as SubQ(TM).

A copy of the Company's press release is attached hereto as Exhibit

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 8-K

99.1.

Item 7. Financial Statements and Exhibits

(a) Financial Statements of Business Acquired.

Not Applicable.

(b) Pro Forma Financial Information.

Not Applicable.

(c) Exhibits.

99.1 Copy of press release, dated July 15, 2004, issued by Medicis  
Pharmaceutical Corporation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,  
the Registrant has duly caused this Report to be signed on its behalf by the  
undersigned hereunto duly authorized.

MEDICIS PHARMACEUTICAL CORPORATION  
(Registrant)

Date: July 15, 2004

/s/ Mark A. Prygocki, Sr.  
-----

Name: Mark A. Prygocki, Sr.  
Title: Executive Vice President,  
Chief Financial Officer,  
Corporate Secretary and  
Treasurer

EXHIBIT INDEX

EXHIBIT NUMBER -----	DESCRIPTION -----
99.1	Copy of press release, dated July 15, 2004, issued by Medicis Pharmaceutical Corporation